Sonnet BioTherapeutics Holdings, Inc. Company Profile: Board of Directors, Capital Structure, Raw Materials & More

Company CV

About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc.

Pharmaceuticals & Biotechnology

Sonnet Biotherapeutics Holdings Inc, formerly Chanticleer Holdings, Inc., an oncology-focused biotechnology company. The Company is developing targeted biologic drugs with enhanced single or bispecific mechanisms.

Company Coordinates

Company Details

100 Overlook Center, Suite 102 , PRINCETON NJ : 08540

Tel: 1 609 3752227

http://www.chanticleerholdings.com/

Registrar Details

Shareholding

Shareholding Snapshot

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.81%)

Foreign Institutions

Held by 4 Foreign Institutions (4.36%)

Strategic Entities with highest holding

Highest Public shareholder

Board of Directors

Management

Designation

Dr. Pankaj Mohan

Chairman of the Board, President, Chief Executive Officer

Mr. Nailesh Bhatt

Director

Mr. Albert Dyrness

Director

Mr. Donald Griffith

Director

Mr. Raghu Rao

Director

Stock DNA

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-4 Million

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 22 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.08

Return on Equity

444.59%

Price to Book

-7.29